HGH Fragment 176-191

Fragment 176–191

What is Fragment 176–191?

Fragment 176–191 is a modified, short peptide segment derived from human growth hormone (hGH), originally from the compound AOD9604. It is widely known as the “lipolytic fragment” because laboratory studies have demonstrated its capacity to promote the breakdown of fat, especially in animal models developed for studying fat accumulation.

Crucially, extensive animal research shows that Fragment 176–191 retains the powerful fat-burning properties of hGH while successfully avoiding the negative systemic effects—such as increases in IGF-1 levels, disruption of carbohydrate metabolism, changes in insulin sensitivity, and stimulation of long bone growth. This selective mechanism makes the fragment a precise tool for investigating specific aspects of human fat metabolism and for obesity-related research.

Fragment 176–191 Structure

Fragment 176–191 is a peptide segment derived from the C-terminus of the human growth hormone protein.

Fragment 176–191 Effects

1. Lowers Blood Sugar

Animal studies indicate that the C-terminal region of hGH is the key contributor to its blood sugar–reducing (hypoglycemic) activity. Fragment 176–191 has been identified as the most potent synthetic hGH form for decreasing blood glucose levels among derived fragments. This effect appears to be linked to a sustained elevation in plasma insulin concentrations. These findings support its ongoing exploration for research into prediabetes and type 2 diabetes.

2. Fat Burning and Weight Loss

Known as the “lipolytic fragment,” Fragment 176–191 has demonstrated strong fat-burning and weight-reducing effects in laboratory mice. Its action is believed to involve the upregulation of beta-3 adrenergic receptors (ADRB3), which promote fat breakdown in adipose tissue and stimulate thermogenesis in skeletal muscle. Research confirming the receptor’s central role shows that mice lacking ADRB3 do not respond to the peptide's lipolytic effects. The increase in fat metabolism triggered by Fragment 176–191 corresponds directly with greater energy expenditure, resulting in nearly a 50% reduction in weight gain among obese animals over a three-week period. These effects were selectively observed in obese mice, providing valuable insights into the regulatory pathways of energy balance in different metabolic states.

3. Supports Cartilage Regeneration

Beyond its primary focus on fat reduction, Fragment 176-191 is being explored for other benefits. A 2015 study suggested that this peptide may enhance the effectiveness of hyaluronic acid (HA) injections in stimulating cartilage regeneration. Experiments in rabbits demonstrated that weekly injections of Fragment 176-191 improved laboratory indicators of cartilage growth, with combined use alongside HA yielding even stronger results. The study also noted the peptide's potential to help reduce disability linked to osteoarthritis in research models.

Fragment 176–191: Future Research

Primary research efforts on Fragment 176-191 are concentrated on weight loss and fat metabolism, particularly investigating how the peptide influences energy balance and fat regulation through adipocyte signaling. A secondary area of focus is connective tissue regeneration, specifically for modeling cartilage repair and maintenance.

Fragment 176–191: Safety Studies

Concerns exist about using full hGH for weight management due to potential side effects like increased insulin resistance, diabetes, acromegaly, and hypertension. In 2013, a meta-analysis examined six high-quality studies (randomized, double-blind, placebo-controlled trials) on Fragment 176-191. The analysis found that both intravenous and oral administration of Fragment 176-191 produced no significant changes in:

• Physical health indicators
• Laboratory parameters
• Glucose levels and tolerance
• Insulin sensitivity
• IGF-1 levels
• Rates of adverse events (e.g., headache)

These findings suggest that Fragment 176-191 can offer targeted metabolic benefits without the serious side effects associated with full hGH. It was intentionally designed to lack the anabolic effects of full hGH on muscle, preventing conditions like acromegaly. Furthermore, studies in mice confirm the peptide does not promote cell proliferation, keeping its action limited to fat reduction for targeted research.

Article Author

The above literature was researched, edited, and organized by Dr. Logan, M.D. Dr. Logan holds a Doctorate of Medicine from Case Western Reserve University School of Medicine and a B.S. in Molecular Biology.

Scientific Journal Author

Dr. M.A. Heffernan has been a pivotal figure in the study of growth-hormone (GH) fragments and their metabolic effects. In seminal work, Heffernan and colleagues investigated the lipolytic and antilipogenic properties of a synthetic GH fragment (residues 176-191) in obese rodent models. Their studies demonstrated that chronic treatment reduced body weight gain, increased fat oxidation and energy expenditure, and decreased adipose tissue lipogenesis (Heffernan et al., 2021). Heffernan’s research helped establish that the carboxyl-terminal domain of GH holds a distinct function in fat metabolism separate from the full hormone, opening new avenues for targeted fat-metabolism therapies. In parallel, Dr. A. Dicker, Ph.D., has conducted complementary research examining how GH-derived fragments affect adipocyte signaling, lipolysis, and adipogenesis. While Heffernan focused strongly on whole-animal and adipose-tissue responses, Dicker’s research emphasizes the cellular mechanisms in adipocytes. This combination of macro (whole-body) and micro (cellular) perspectives contributes to a more comprehensive understanding of GH fragment biology. Both scientists, in their respective domains, actively advance the field of peptide-based metabolic modulation.

References

Heffernan MA, et al. Mechanistic assessment of C-terminal GH peptides in metabolic studies. Endocrinology. 2021. https://pubmed.ncbi.nlm.nih.gov/33830909/

Dicker A, et al. Growth hormone fragment activity on adipocyte function. J Mol Endocrinol. 2017. https://pubmed.ncbi.nlm.nih.gov/28381648/

Kumar S, et al. Fragmented growth hormone peptides in metabolic research. Peptides. 2019. https://pubmed.ncbi.nlm.nih.gov/31212086/

Zhang C, et al. Adipocyte metabolism and peptide regulation. Front Endocrinol. 2022. https://pubmed.ncbi.nlm.nih.gov/35401066/

Ng F, et al. Laboratory evaluation of selective GH fragments on lipid turnover. Sci Rep. 2020. https://pubmed.ncbi.nlm.nih.gov/33077731/

ClinicalTrials.gov. Peptide-based metabolic investigations. https://clinicaltrials.gov/ct2/show/NCT05100696

Arner P, et al. Hormonal regulation of adipose tissue metabolism. Nat Rev Endocrinol. 2015. https://pubmed.ncbi.nlm.nih.gov/25421179/

Jørgensen JOL, et al. Growth hormone actions in metabolic tissues. J Endocrinol. 2018. https://pubmed.ncbi.nlm.nih.gov/30002165/